FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1529483773> ?p ?o ?g. }

• W1529483773 abstract "Background Approximately one-third of individuals with interstitial lung disease (ILD) have associated connective tissue disease (CTD). The connective tissue disorders most commonly associated with ILD include scleroderma/systemic sclerosis (SSc), rheumatoid arthritis, polymyositis/dermatomyositis, and Sjogren's syndrome. Although many people with CTD-ILD do not develop progressive lung disease, a significant proportion do progress, leading to reduced physical function, decreased quality of life, and death. ILD is now the major cause of death amongst individuals with systemic sclerosis.Cyclophosphamide is a highly potent immunosuppressant that has demonstrated efficacy in inducing and maintaining remission in autoimmune and inflammatory illnesses. However this comes with potential toxicities, including nausea, haemorrhagic cystitis, bladder cancer, bone marrow suppression, increased risk of opportunistic infections, and haematological and solid organ malignancies.Decision-making in the treatment of individuals with CTD-ILD is difficult; the clinician needs to identify those who will develop progressive disease, and to weigh up the balance between a high level of need for therapy in a severely unwell patient population against the potential for adverse effects from highly toxic therapy, for which only relatively limited data on efficacy can be found. Similarly, it is not clear whether histological subtype, disease duration, or disease extent can be used to predict treatment responsiveness. Objectives To assess the efficacy and adverse effects of cyclophosphamide in the treatment of individuals with CTD-ILD. Search methods We performed searches on CENTRAL, MEDLINE, Embase, CINAHL, and Web of Science up to May 2017. We handsearched review articles, clinical trial registries, and reference lists of retrieved articles. Selection criteria We included randomised controlled parallel-group trials that compared cyclophosphamide in any form, used individually or concomitantly with other immunomodulating therapies, versus non-cyclophosphamide-containing therapies for at least six months, with follow-up of at least 12 months from the start of treatment. Data collection and analysis We imported studies identified by the search into a reference manager database. We retrieved the full-text versions of relevant studies, and two review authors independently extracted data. Primary outcomes were change in lung function (change in forced vital capacity (FVC) % predicted and diffusing capacity of the lung for carbon monoxide (DLCO) % predicted), adverse events, and health-related quality of life measures. Secondary outcomes included all-cause mortality, dyspnoea, cough, and functional exercise testing. When appropriate, we performed meta-analyses and subgroup analyses by severity of lung function, connective tissue disease diagnosis, and radiological pattern of fibrosis. We assessed the evidence using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach and created 'Summary of findings' tables. Main results We included in the analysis four trials with 495 participants (most with systemic sclerosis). We formed two separate comparisons: cyclophosphamide versus placebo (two trials, 195 participants) and cyclophosphamide versus mycophenolate (two trials, 300 participants). We found evidence to be of low quality, as dropout rates were high in the intervention groups, and as we noted a wide confidence interval around the effect with small differences, which affected the precision of results.The data demonstrates significant improvement in lung function with cyclophosphamide compared with placebo (post-treatment FVC % mean difference (MD) 2.83, 95% confidence interval (CI) 0.80 to 4.87; P = 0.006) but no significant difference in post-treatment DLCO (% MD -1.68, 95% CI -4.37 to 1.02; P = 0.22; two trials, 182 participants).Risk of adverse effects was increased in the cyclophosphamide treatment groups compared with the placebo groups, in particular, haematuria, leukopenia, and nausea, leading to a higher rate of withdrawal from cyclophosphamide treatment. The data demonstrates statistically significant improvement in one-measure of quality of life in one trial favouring cyclophosphamide over placebo and clinically and statistically significant improvement in breathlessness in one trial favouring cyclophosphamide compared with placebo, with no significant impact on mortality.Trialists reported no significant impact on lung function when cyclophosphamide was used compared with mycophenolate at 12 months (FVC % MD -0.82, 95% CI -3.95 to 2.31; P = 0.61; two trials, 149 participants; DLCO % MD -1.41, 95% CI -10.40 to 7.58; P = 0.76; two trials, 149 participants).Risk of side effects was increased with cyclophosphamide versus mycophenolate, in particular, leukopenia and thrombocytopenia.The data demonstrates no significant impact on health-related quality of life, all-cause mortality, dyspnoea, or cough severity in the cyclophosphamide group compared with the mycophenolate group. No trials reported outcomes associated with functional exercise tests.We performed subgroup analysis to determine whether severity of lung function, connective tissue disease diagnosis, or radiological pattern had any impact on outcomes. One trial reported that cyclophosphamide protected against decreased FVC in individuals with worse fibrosis scores, and also showed that cyclophosphamide may be more effective in those with worse lung function. No association could be made between connective tissue disease diagnosis and outcomes. Authors' conclusions This review, which is based on studies of varying methodological quality, demonstrates that overall, in this population, small benefit may be derived from the use of cyclophosphamide in terms of mean difference in % FVC when compared with placebo, but not of the difference in % DLCO, or when compared with mycophenolate. Modest clinical improvement in dyspnoea may be noted with the use of cyclophosphamide. Clinical practice guidelines should advise clinicians to consider individual patient characteristics and to expect only modest benefit at best in preserving FVC. Clinicians should carefully monitor for adverse effects during treatment and in the years thereafter.Further studies are required to examine the use of cyclophosphamide; they should be adequately powered to compare outcomes within different subgroups, specifically, stratified for extent of pulmonary infiltrates on high-resolution computed tomography (HRCT) and skin involvement in SSc. Studies on other forms of connective tissue disease are needed. Researchers may consider comparing cyclophosphamide (a potent immunosuppressant) versus antifibrotic agents, or comparing both versus placebo, in particular, for those with evidence of rapidly progressive fibrotic disease, who may benefit the most." @default.
• W1529483773 created "2016-06-24" @default.
• W1529483773 creator A5020380947 @default.
• W1529483773 creator A5022121883 @default.
• W1529483773 creator A5025045708 @default.
• W1529483773 creator A5030727574 @default.
• W1529483773 creator A5030988190 @default.
• W1529483773 date "2018-01-03" @default.
• W1529483773 modified "2023-10-17" @default.
• W1529483773 title "Cyclophosphamide for connective tissue disease-associated interstitial lung disease" @default.
• W1529483773 cites W1910502462 @default.
• W1529483773 cites W1932542775 @default.
• W1529483773 cites W1966466614 @default.
• W1529483773 cites W1967763945 @default.
• W1529483773 cites W1971058219 @default.
• W1529483773 cites W1977926705 @default.
• W1529483773 cites W1993533928 @default.
• W1529483773 cites W2011309580 @default.
• W1529483773 cites W2016046064 @default.
• W1529483773 cites W2017990928 @default.
• W1529483773 cites W2022441502 @default.
• W1529483773 cites W2022725035 @default.
• W1529483773 cites W2024442997 @default.
• W1529483773 cites W2033262426 @default.
• W1529483773 cites W2038987705 @default.
• W1529483773 cites W2041443103 @default.
• W1529483773 cites W2042608110 @default.
• W1529483773 cites W2042926190 @default.
• W1529483773 cites W2050362215 @default.
• W1529483773 cites W2056364917 @default.
• W1529483773 cites W2061400484 @default.
• W1529483773 cites W2077262698 @default.
• W1529483773 cites W2084449053 @default.
• W1529483773 cites W2089836290 @default.
• W1529483773 cites W2095657111 @default.
• W1529483773 cites W2095975942 @default.
• W1529483773 cites W2098305693 @default.
• W1529483773 cites W2098471340 @default.
• W1529483773 cites W2103168499 @default.
• W1529483773 cites W2103258766 @default.
• W1529483773 cites W2105647513 @default.
• W1529483773 cites W2106261552 @default.
• W1529483773 cites W2115503161 @default.
• W1529483773 cites W2116531828 @default.
• W1529483773 cites W2119115210 @default.
• W1529483773 cites W2119857070 @default.
• W1529483773 cites W2125049108 @default.
• W1529483773 cites W2131014787 @default.
• W1529483773 cites W2132135090 @default.
• W1529483773 cites W2132316558 @default.
• W1529483773 cites W2132946922 @default.
• W1529483773 cites W2133932878 @default.
• W1529483773 cites W2134547880 @default.
• W1529483773 cites W2138442131 @default.
• W1529483773 cites W2147543851 @default.
• W1529483773 cites W2156807514 @default.
• W1529483773 cites W2285186378 @default.
• W1529483773 cites W2295461102 @default.
• W1529483773 cites W2312405350 @default.
• W1529483773 cites W2312704633 @default.
• W1529483773 cites W2316578352 @default.
• W1529483773 cites W2324693904 @default.
• W1529483773 cites W2327137468 @default.
• W1529483773 cites W2334323498 @default.
• W1529483773 cites W2416914730 @default.
• W1529483773 cites W2418807167 @default.
• W1529483773 cites W2498506084 @default.
• W1529483773 cites W2561237922 @default.
• W1529483773 cites W2605548119 @default.
• W1529483773 cites W4253744074 @default.
• W1529483773 doi "https://doi.org/10.1002/14651858.cd010908.pub2" @default.
• W1529483773 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6491200" @default.
• W1529483773 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29297205" @default.
• W1529483773 hasPublicationYear "2018" @default.
• W1529483773 type Work @default.
• W1529483773 sameAs 1529483773 @default.
• W1529483773 citedByCount "62" @default.
• W1529483773 countsByYear W15294837732019 @default.
• W1529483773 countsByYear W15294837732020 @default.
• W1529483773 countsByYear W15294837732021 @default.
• W1529483773 countsByYear W15294837732022 @default.
• W1529483773 countsByYear W15294837732023 @default.
• W1529483773 crossrefType "journal-article" @default.
• W1529483773 hasAuthorship W1529483773A5020380947 @default.
• W1529483773 hasAuthorship W1529483773A5022121883 @default.
• W1529483773 hasAuthorship W1529483773A5025045708 @default.
• W1529483773 hasAuthorship W1529483773A5030727574 @default.
• W1529483773 hasAuthorship W1529483773A5030988190 @default.
• W1529483773 hasBestOaLocation W15294837732 @default.
• W1529483773 hasConcept C126322002 @default.
• W1529483773 hasConcept C142724271 @default.
• W1529483773 hasConcept C2776670291 @default.
• W1529483773 hasConcept C2776694085 @default.
• W1529483773 hasConcept C2776755627 @default.
• W1529483773 hasConcept C2777543607 @default.
• W1529483773 hasConcept C2777714996 @default.
• W1529483773 hasConcept C2779075594 @default.
• W1529483773 hasConcept C2779134260 @default.
• W1529483773 hasConcept C518705261 @default.
• W1529483773 hasConcept C71924100 @default.

• next